Vir Biotechnology, Inc. (VIR) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
Vir Biotechnology, Inc. (VIR) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$94.96 MLiabilities$232.31 MCurrent assets$573.74 MNon-current liabilities$137.35 MEquity$982.49 MGross equity(calculated)$2.23 BAssets$1.21 BNon-current assets$641.07 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsShort-term investmentsPrepaid expenses and other current assetsEquity investmentsRestricted cash and cash equivalents, currentLong-term investmentsOperating right-of-use assetsProperty and equipment, netOther assetsGoodwillIntangible assets, netRestricted cash and cash equivalents, noncurrentAccrued and other liabilitiesAccounts payableOperating lease liabilities, noncurrentContingent consideration obligation, noncurrentOther long-term liabilitiesAdditional paid-in capitalCommon stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 169,185,671 and 139,474,954 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccumulated other comprehensive lossCurrent liabilitiesCurrent liabilities$94.96 MAccrued and other liabilitiesAccrued and other liabilities$77.21 MLiabilitiesLiabilities$232.31 MAccounts payableAccounts payable$17.75 MOperating lease liabilities, noncurrentOperating lease liabilities, noncurrent$84.14 MCurrent assetsCurrent assets$573.74 MCash and cash equivalentsCash and cash equivalents$278.73 MNon-current liabilitiesNon-current liabilities$137.35 MContingent consideration obligation, noncurrentContingent consideration obligation, noncurrent$34.34 MEquityEquity$982.49 MShort-term investmentsShort-term investments$249.86 MOther long-term liabilitiesOther long-term liabilities$18.88 MGross equity (calculated)Gross equity(calculated)$2.23 BAssetsAssets$1.21 BPrepaid expenses and other current assetsPrepaid expenses and other current assets$39.08 MEquity investmentsEquity investments$4.13 MRestricted cash and cash equivalents, currentRestricted cash and cash equivalents, current$1.93 MLong-term investmentsLong-term investments$475.02 MNon-current assetsNon-current assets$641.07 MOperating right-of-use assetsOperating right-of-use assets$59.39 MAdditional paid-in capitalAdditional paid-in capital$2.23 BProperty and equipment, netProperty and equipment, net$50.43 MOther assetsOther assets$24.65 MGoodwillGoodwill$16.94 MIntangible assets, netIntangible assets, net$7.70 MRestricted cash and cash equivalents, noncurrentRestricted cash and cash equivalents, noncurrent$6.94 MCommon stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 169,185,671 and 139,474,954 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock$17.00 KAccumulated deficitAccumulated deficit−$1.24 BAccumulated other comprehensive lossAccumulated other comprehensive loss−$4.60 M
Chart details

Vir Biotechnology, Inc. (VIR) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
1,214,806,000 US dollars
Current assets
573,739,000 US dollars
Non-current assets
641,067,000 US dollars
Liabilities
232,313,000 US dollars
Current liabilities
94,961,000 US dollars
Non-current liabilities
137,352,000 US dollars
Equity
982,493,000 US dollars
Cash and cash equivalents
278,729,000 US dollars
Short-term investments
249,864,000 US dollars
Prepaid expenses and other current assets
39,084,000 US dollars
Equity investments
4,133,000 US dollars
Restricted cash and cash equivalents, current
1,929,000 US dollars
Long-term investments
475,016,000 US dollars
Operating right-of-use assets
59,391,000 US dollars
Property and equipment, net
50,430,000 US dollars
Other assets
24,647,000 US dollars
Goodwill
16,937,000 US dollars
Intangible assets, net
7,702,000 US dollars
Restricted cash and cash equivalents, noncurrent
6,944,000 US dollars
Accrued and other liabilities
77,207,000 US dollars
Accounts payable
17,754,000 US dollars
Operating lease liabilities, noncurrent
84,137,000 US dollars
Contingent consideration obligation, noncurrent
34,340,000 US dollars
Other long-term liabilities
18,875,000 US dollars
Additional paid-in capital
2,230,464,000 US dollars
Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 169,185,671 and 139,474,954 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
17,000 US dollars
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
0 US dollars
Accumulated deficit
negative 1,243,386,000 US dollars
Accumulated other comprehensive loss
negative 4,602,000 US dollars
Gross equity (calculated)
2,230,481,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
Vir Biotechnology, Inc. (VIR) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!